WVE (WAVE Life Sciences) Total Liabilities : $142.7 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences Total Liabilities?

WAVE Life Sciences's Total Liabilities for the quarter that ended in Dec. 2024 was $142.7 Mil.

WAVE Life Sciences's quarterly Total Liabilities increased from Jun. 2024 ($212.30 Mil) to Sep. 2024 ($216.86 Mil) but then declined from Sep. 2024 ($216.86 Mil) to Dec. 2024 ($142.69 Mil).

WAVE Life Sciences's annual Total Liabilities increased from Dec. 2022 ($191.48 Mil) to Dec. 2023 ($235.32 Mil) but then declined from Dec. 2023 ($235.32 Mil) to Dec. 2024 ($142.69 Mil).

WAVE Life Sciences Total Liabilities Historical Data

The historical data trend for WAVE Life Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Total Liabilities Chart

WAVE Life Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

196.46

174.51

191.48

235.32

142.69

WAVE Life Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															235.32	209.88	212.30	216.86	142.69

WAVE Life Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

WAVE Life Sciences's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	110.953	+	(17.766	+	7.874
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	6.099	+	0	+	0)
	=	142.7

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	352.207	-	209.515
	=	142.7

WAVE Life Sciences's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	110.953	+	(17.766	+	7.874
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	6.099	+	0	+	0)
	=	142.7

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	352.207	-	209.515
	=	142.7

WAVE Life Sciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

WAVE Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

1U5:Germany

Address

7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936

Website

https://www.wavelifesciences.com

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Executives

Paul Bolno	director, officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Kyle Moran	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Chandra Vargeese	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Michael A. Panzara	officer: Franchise Lead, Neurology	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero	officer: Interim CFO	733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Heidi L Wagner	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Amy Pott	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Mark Corrigan	director